MBOT Relative Valuation
MBOT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MBOT is overvalued; if below, it's undervalued.
Historical Valuation
Microbot Medical Inc (MBOT) is now in the Fair zone, suggesting that its current forward PS ratio of 55.41 is considered Fairly compared with the five-year average of -4.59. The fair price of Microbot Medical Inc (MBOT) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.11
Fair
-6.59
PE
1Y
3Y
5Y
-2.82
EV/EBITDA
Microbot Medical Inc. (MBOT) has a current EV/EBITDA of -2.82. The 5-year average EV/EBITDA is -0.13. The thresholds are as follows: Strongly Undervalued below -1.52, Undervalued between -1.52 and -0.83, Fairly Valued between 0.56 and -0.83, Overvalued between 0.56 and 1.26, and Strongly Overvalued above 1.26. The current Forward EV/EBITDA of -2.82 falls within the Strongly Undervalued range.
-2.81
EV/EBIT
Microbot Medical Inc. (MBOT) has a current EV/EBIT of -2.81. The 5-year average EV/EBIT is -2.92. The thresholds are as follows: Strongly Undervalued below -27.77, Undervalued between -27.77 and -15.34, Fairly Valued between 9.50 and -15.34, Overvalued between 9.50 and 21.92, and Strongly Overvalued above 21.92. The current Forward EV/EBIT of -2.81 falls within the Historic Trend Line -Fairly Valued range.
55.41
PS
Microbot Medical Inc. (MBOT) has a current PS of 55.41. The 5-year average PS is 815.39. The thresholds are as follows: Strongly Undervalued below -8327.44, Undervalued between -8327.44 and -3756.02, Fairly Valued between 5386.80 and -3756.02, Overvalued between 5386.80 and 9958.22, and Strongly Overvalued above 9958.22. The current Forward PS of 55.41 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Microbot Medical Inc. (MBOT) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Microbot Medical Inc. (MBOT) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Microbot Medical Inc (MBOT) has a current Price-to-Book (P/B) ratio of 1.78. Compared to its 3-year average P/B ratio of 3.50 , the current P/B ratio is approximately -49.27% higher. Relative to its 5-year average P/B ratio of 3.41, the current P/B ratio is about -47.89% higher. Microbot Medical Inc (MBOT) has a Forward Free Cash Flow (FCF) yield of approximately -7.78%. Compared to its 3-year average FCF yield of -40.36%, the current FCF yield is approximately -80.73% lower. Relative to its 5-year average FCF yield of -33.17% , the current FCF yield is about -76.55% lower.
1.78
P/B
Median3y
3.50
Median5y
3.41
-7.78
FCF Yield
Median3y
-40.36
Median5y
-33.17
Competitors Valuation Multiple
The average P/S ratio for MBOT's competitors is 17.78, providing a benchmark for relative valuation. Microbot Medical Inc Corp (MBOT) exhibits a P/S ratio of 55.41, which is 211.61% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MBOT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MBOT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Microbot Medical Inc (MBOT) currently overvalued or undervalued?
Microbot Medical Inc (MBOT) is now in the Fair zone, suggesting that its current forward PS ratio of 55.41 is considered Fairly compared with the five-year average of -4.59. The fair price of Microbot Medical Inc (MBOT) is between to according to relative valuation methord.
What is Microbot Medical Inc (MBOT) fair value?
MBOT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Microbot Medical Inc (MBOT) is between to according to relative valuation methord.
How does MBOT's valuation metrics compare to the industry average?
The average P/S ratio for MBOT's competitors is 17.78, providing a benchmark for relative valuation. Microbot Medical Inc Corp (MBOT) exhibits a P/S ratio of 55.41, which is 211.61% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Microbot Medical Inc (MBOT) as of Jan 08 2026?
As of Jan 08 2026, Microbot Medical Inc (MBOT) has a P/B ratio of 1.78. This indicates that the market values MBOT at 1.78 times its book value.
What is the current FCF Yield for Microbot Medical Inc (MBOT) as of Jan 08 2026?
As of Jan 08 2026, Microbot Medical Inc (MBOT) has a FCF Yield of -7.78%. This means that for every dollar of Microbot Medical Inc’s market capitalization, the company generates -7.78 cents in free cash flow.
What is the current Forward P/E ratio for Microbot Medical Inc (MBOT) as of Jan 08 2026?
As of Jan 08 2026, Microbot Medical Inc (MBOT) has a Forward P/E ratio of -6.59. This means the market is willing to pay $-6.59 for every dollar of Microbot Medical Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Microbot Medical Inc (MBOT) as of Jan 08 2026?
As of Jan 08 2026, Microbot Medical Inc (MBOT) has a Forward P/S ratio of 55.41. This means the market is valuing MBOT at $55.41 for every dollar of expected revenue over the next 12 months.